SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
NEW YORK, Feb. 16, 2016 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 2016 RBC Capital Markets’ Healthcare Conference. The presentation is scheduled for Tuesday, February 23rd, 2016 at 11:00 am EST.
The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia and bipolar depression. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.
Contact: Juan Sanchez, M.D. Vice President Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc. Phone: 212-923-3344 Burns McClellan, Inc. Lisa Burns Justin Jackson (Media) [email protected] 212-213-0006
